| Summary: | 碩士 === 國立中興大學 === 生命科學院碩士在職專班 === 103 === Candida bacteremia cases increasing in various hospitals of the world, especially in immunocompromised, prior immunosuppressive therapy, chemotherapy, hemodialysis, total parenteral nutrition, central venous catheter injection , and other invasive medical devices, Candida parapsilosis complex caused by colonization and infection of patients, even the outbreak of nosocomial infection. In 1992, Lehmann et al. suggested that C. parapsilosis isolates can be divided into groupⅠ,Ⅱ, and Ⅲ on the basis of randomly amplified polymorphic DNA (RAPD) results. However, Tavanti et al. (2005) found C. parapsilosis groupⅠcompared with groupⅡand Ⅲ of DNA sequences similarities were less than 90% in the ITS1 sequence, and formally designate C. parapsilosis groups II and III as the new species C. orthopsilosis and C. metapsilosis on the grounds. This study included 101 C. parapsilosis complex strains identified among blood sample isolates collected from June 2009 to August 2014 in China Medical University Hospital. Identification of the C . parapsilosis was tested using API ID 32C .Formic acid extraction sample was identified by Matrix-assisted laser desorption / ionization time-of-flight (MALDI-TOF) mass spectrometry, the result for C. parapsilosis 75 strains (75/101) 74%, C. orthopsilosis 11 strains (11/101) 11%, C. metapsilosis 15 strains (11/101) 15%. Exon-primed intron-crossing polymerase chain reaction (EPIC-PCR) was used to verify the results of MALDI-TOF, Both of the MALDI-TOF findings and EPIC-PCR results with 100% compliance. This study proved that MALDI-TOF mass spectrometry for differentiation of C. parapsilosis complex, will become a rapid and accurate method to distinguish among C. parapsilosis complex in clinical laboratory.
|
|---|
